Elysian announced its selection to Lloyd's Lab Cohort 16, the accelerator program at the heart of the world's largest specialty insurance market The post ElysianElysian announced its selection to Lloyd's Lab Cohort 16, the accelerator program at the heart of the world's largest specialty insurance market The post Elysian

Elysian Selected for Lloyd’s Lab Cohort 16 to Advance AI-Native Claims Auditing for the Global Specialty Market

2026/03/10 08:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Elysian, the first AI-native third-party administrator (TPA) built for commercial claims, announced its selection to Lloyd’s Lab Cohort 16, the accelerator program at the heart of the world’s largest specialty insurance market. The program received 220 applications globally. Twenty companies were shortlisted to present at a Pitch Day at Lloyd’s of London on March 4, and Elysian was one of twelve ultimately selected to join the cohort.

The Lloyd’s Lab accelerator pairs selected companies with Lloyd’s managing agents, brokers, and Corporation specialists over a ten-week program to test, refine, and scale solutions for the specialty insurance market. Cohort 16 focuses on three themes: operational efficiency in the Lloyd’s market, new products for emerging risks, and an Ireland-specific resilience initiative developed in partnership with the Irish Department of Finance. Elysian was selected under the operational efficiency theme for its work in commercial claims auditing and focus on efficient quality claims adjusting.

Elysian serves MGAs, MGUs, insurance carriers, fronting carriers, self-insureds, and reinsurers through two core offerings: AI-Enhanced Claims Quality Assurance, powered by its Dynamic Claim Review technology, and full-service End-to-End Claims Handling TPA Services. The company’s quality assurance capabilities enable auditing across 100% of a claims portfolio while claims are still open and handling decisions can still be corrected, in an industry where only about 5% of claims are typically reviewed, often retroactively and by hand.

During the program, Elysian will work with Lloyd’s market participants to adapt its Claim Conductor platform for Lloyd’s specialty lines, with a focus on real-time claims quality review, coverholder and TPA oversight, and syndicate compliance reporting.

“While Chief Claims Officer at Hiscox Syndicate 33, the oldest syndicate in the Lloyd’s market, I developed a deep respect for what this ecosystem demands from its participants,” said Grace Hanson, Founder and CEO of Elysian. “The complexity of specialty lines require a level of rigor in claims oversight that traditional approaches struggle to deliver at scale. This program gives us the opportunity to prove our technology within Lloyd’s and develop the right approach for this market.”

Hanson, a five-time Chief Claims Officer with executive tenures at AIG, Allied World, Homesite, Hiscox, and Hippo, founded Elysian to address persistent inefficiencies in complex commercial claims processing. Her leadership team has collectively managed over $50 billion in reserves across global carriers in the United States, United Kingdom, and Bermuda.

The selection to Lloyd’s Lab follows recent recognitions including the CB Insights Insurtech 50, the State Farm Startup Pitch Competition win at ITC Vegas, and inclusion in the Gallagher Re Global InsurTech Report.

The post Elysian Selected for Lloyd’s Lab Cohort 16 to Advance AI-Native Claims Auditing for the Global Specialty Market appeared first on FF News | Fintech Finance.

Market Opportunity
LAB Logo
LAB Price(LAB)
$0.15796
$0.15796$0.15796
-2.30%
USD
LAB (LAB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.